Objectives: Whole-heart coronary magnetic resonance angiography (MRA) is a promising non-contrast, radiation-free technique for assessing the coronary artery. Yet, a disadvantage of coronary MRA is the relatively long acquisition time. The purpose of this study was to evaluate the scan time and image quality of compressed sensing (CS) coronary MRA compared with conventional coronary MRA.
Materials And Methods: Twenty healthy volunteers underwent navigator-gated coronary MRA with a CS prototype sequence and conventional navigator-gated coronary MRA on a clinical 3T MRI scanner without contrast medium. The spatial resolutions were 1.33 × 1.33 × 1.20 mm for CS and 1.33 × 1.33 × 1.48 mm interpolated to 0.70 × 0.70 × 1.20 mm for conventional, respectively. We compared acquisition times, rated image quality on a 4-point scale (RCA; proximal, middle, and distal, LAD; main, proximal, middle, and distal, LCX; proximal and distal), and measured the visualized vessel lengths of three vessels.
Results: The mean acceptance rates were 44.9% for CS coronary MRA and 48.7% for conventional coronary MRA (p = .39). The mean effective scan time was 3 min 45 s for CS coronary MRA and 15 min 6 s for conventional coronary MRA (p < 0.001). Image quality scores were significantly lower for CS coronary MRA than for conventional coronary MRA (3.4 ± 0.7 for CS vs. 3.8 ± 0.4 for conventional; p < 0.0001). Conventional coronary MRA images were scored >3.4 in all segments on average, while CS coronary MRA images were scored >3.2 (good quality for diagnosis) in almost all segments, with only the distal RCA segment graded 2.9 on average. The average visible vessel lengths for CS and conventional coronary MRA were as follows: 11.5 ± 4.4 cm and 12.5 ± 4.8 cm for the RCA, respectively (p < 0.05, 95% limits of agreement [LOA]; -3.6 to 1.6 cm); 10.6 ± 3.0 cm and 11.1 ± 2.9 cm for the LAD, respectively (p = .15, 95% LOA -4.0 to 2.8 cm); and 7.1 ± 2.2 cm and 8.2 ± 2.5 cm for the LCX, respectively (p < 0.05, 95% LOA -4.0 to 1.7 cm).
Conclusions: Non-contrast coronary MRA using CS could largely shorten acquisition time, compared with conventional navigator-gated coronary MRA, while maintaining acceptable visualization at 3T.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejrad.2018.04.025 | DOI Listing |
Front Pharmacol
December 2024
Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Introduction: To clarify the efficacy of mineralocorticoid receptor antagonists (MRA) and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) in heart failure with mildly reduced ejection fraction (HFmrEF).
Methods: This study assessed the association between these medications and outcomes in HFmrEF using data from the National Taiwan University Hospital-integrated Medical Database. The primary outcome was cardiovascular mortality/heart failure hospitalization (HHF).
Am Heart J Plus
December 2024
National Institute of Cardiology Ignacio Chavez, Coronary Care Unit, Mexico City, Mexico.
Background And Aims: Heart failure with preserved ejection fraction (HFpEF) is an increasingly common clinical syndrome, estimated to constitute approximately 50 % of all heart failure (HF) cases. Nonetheless, registries from specific geographic areas, as Latin America, are lacking. The present study aims to report the underlying causes, comorbidities, treatment patterns and outcomes of patients with HFpEF in a large cardiovascular center in Mexico City.
View Article and Find Full Text PDFG Ital Cardiol (Rome)
January 2025
U.O.C. Cardiologia 1, Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo.
Mineralocorticoid receptor antagonists (MRAs) represent one of the cornerstones of treatment for heart failure with reduced ejection fraction. Post-hoc data from the TOPCAT trial, conducted in patients with heart failure mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), suggest the possible clinical benefit of MRAs, particularly for slightly reduced ejection fraction values. The advent of non-steroidal MRAs, including finerenone, seems to represent a turning point in the treatment for HFmrEF/HFpEF.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Cardiovascular Medicine, the Heart Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Background: Much remains to be learned about patients with heart failure with improved ejection fraction (HFimpEF).
Objective: This study sheds light on the characteristics and clinical outcomes of HFimpEF patients, including the consequences of halting guideline-directed medical therapy (GDMT).
Methods: This retrospective study was conducted on patients diagnosed with heart failure with reduced ejection fraction (HFrEF) who underwent a second echocardiogram at least 6 months apart between January 2009 and February 2023.
Background: Suboptimal guideline-directed medical therapy (GDMT) management for heart failure (HF) is a critical issue in rural communities. Most patients with HF in rural communities are treated in primary care settings. Multidisciplinary telemedicine-led HF medication optimization clinics were implemented to improve access to specialty care and address health disparities in HF care in rural Appalachian areas.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!